Methods for the diagnosis and treatment of bone disorders

Details Methods for the diagnosis and treatment of bone disorders Methods for the diagnosis and treatment of bone disorders

2011-03-08

2011-03-08

Warden, Jill (Department: 1777)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S025000

Reexamination Certificate

active

07901873

ABSTRACT:
This invention pertains to chemometric methods for the analysis of chemical, biochemical, and biological data, for example, spectral data, for example, nuclear magnetic resonance (NMR) spectra, and their applications, including, e.g., classification, diagnosis, prognosis, etc., especially in the context of bone disorders, e.g., conditions associated with low bone mineral density, e.g., osteoporosis.

REFERENCES:
patent: 4510450 (1985-04-01), Brown
patent: 4635643 (1987-01-01), Brown
patent: 5769074 (1998-06-01), Barnhill et al.
patent: 6683455 (2004-01-01), Ebbels et al.
patent: 2002/0145425 (2002-10-01), Ebbels et al.
patent: 2004/0142496 (2004-07-01), Nicholson et al.
patent: 2004/0214348 (2004-10-01), Nicholson et al.
patent: 2004/0241743 (2004-12-01), Nicholson et al.
patent: 2005/0037515 (2005-02-01), Nicholson et al.
patent: 2005/0074745 (2005-04-01), Clayton et al.
patent: 2005/0130321 (2005-06-01), Nicholson et al.
patent: 2006/0073611 (2006-04-01), Grainger et al.
patent: 2000-298128 (2000-10-01), None
patent: WO-91/10128 (1991-07-01), None
patent: WO-93/21517 (1993-10-01), None
patent: WO-97/48331 (1997-12-01), None
patent: WO-99/45842 (1999-09-01), None
patent: WO-00/42915 (2000-07-01), None
patent: WO-00/65366 (2000-11-01), None
patent: WO-00/72031 (2000-11-01), None
patent: WO-00/72038 (2000-11-01), None
patent: WO-02/085195 (2002-10-01), None
patent: WO-02/085195 (2002-10-01), None
patent: WO-02/086478 (2002-10-01), None
patent: WO-02/086478 (2002-10-01), None
patent: WO-02/086500 (2002-10-01), None
patent: WO-02/086500 (2002-10-01), None
patent: WO-02/086501 (2002-10-01), None
patent: WO-02/086501 (2002-10-01), None
patent: WO-02/086502 (2002-10-01), None
A Microtitre Format Assay for Proline in Human Serum or Plasma David J. Grainger, Sri Aitken Clinica Chimica Acta 343 (2004) 113-118.
Adams, E. et al. (1980). “Metabolism of Proline and the Hydroxprolines,”Ann. Rev. Bio.49:1005-1061.
Ala-Korpela, M. (1995). “1HNMR Spectroscopy of Human Blood Plasma,”Progress in Nuclear Magnetic Resonance Spectroscopy27:475-554.
Ala-Korpela, M. et al. (1995). “Quantification of Biomedical NMR Data using Artificial Neural Network Analysis: Lipoprotein Lipid Profiles from1H NMR Data of Human Plasma,”NMR in Biomedicine8:235-244.
Andersson, C.A. (1999). “Direct Orthogonalization,”Chemonmetrics and Intelligent Laboratory Systems47:51-63.
Anker, L. et al. (1992). “Prediction of Carbon-13 Nuclear Magnetic Resonance Chemical Shifts by Artificial Neural Networks,”Anal. Chem.64:1157-1164.
Anthony, M.L. et al., (1994). “Pattern Recognition Classification of the Site of Nephrotoxicity Based on Metabolic Data Derived from Proton Nuclear Magnetic Resonance Spectra of Urine,”Molecular Pharmacology46:199-211.
Anthony, M.L. et al. (1995). “Classification of Toxin-Induced Changes in1H NMR Spectra of Urine Using an Artificial Neural Network,”Journal of Pharmaceutical&Biomedical Analysis13(3):205-211.
Beckwith-Hall, B.M. et al. (1998). “Nuclear Magnetic Resonance Spectroscopic and Principal Components Analysis Investigation into Biochemical Effects of Three Model Hepatotoxins,”Chem. Res. Toxicol.11:260-272.
Berman, J.L. et al. (Sep. 1978). “A Multivariate Approach for Interpreting Treadmill Exercise Tests in Coronary Artery Disease,”Circulation58(3):505-512.
Berman, J.W. et al. (Apr. 15, 1996). “Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat,”J. of Immunol.156(8):3017-3023.
Bishop, C.M. (1995).Neural Networks for Pattern Recognition, Oxford University Press, Inc.: New York, NY, pp. xiv-xvii (Table of Contents Only.).
Boctor, F.N. (1971). “An Improved Method for Colorimetric Determination of Proline with Isatin,”Analytical Biochemistry43:66-70.
Breslow, J.L. (Sep. 1993). “Transgenic Mouse Models of Lipoprotein Metabolism and Atherosclerosis,”Proc. Natl. Acad. Sci. USA90:8314-8318.
Bretthorst, G.L. et al. (1988). “Bayesian Analysis of Time-Domain Magnetic Resonance Signals,”Journal of Magnetic Resonance79:369-376.
Bretthorst, G.L. (1990). “Bayesian Analysis. II. Signal Detection and Model Selection,”Journal of Magnetic Resonance88:552-570.
Bretthorst, G.L. (1990). “Bayesian Analysis. III. Applications to NMR Signal Detection, Model Selection, and Parameter Estimation,”Journal of Magnetic Resonance88:571-595.
Bro, R. (1997). “PARAFAC. Tutorial and Applications,”Chemometrics and Intelligent Laboratory Systems38:149-171.
Broomhead, D.S. et al. (1998) “Multivariable Function Interpolation and Adaptive Networks,”Complex Systems2:321-355.
Brown, T.R. et al. (1996). “NMR Spectral Quantitation by Principal-Component Analysis. II. Determination of Frequency and Phase Shifts,”Journal of Magnetic Resonance, Series B112:32-43.
Bruce, R.A. (Oct. 1974). Value of the Balke Protocol,American Heart Journal88(4):533-534.
Collins, F.S. et al. (Feb. 7, 2001). “Implications of the Human Genome Project for Medical Science,”Journal of the American Medical Association285(5):540-544.
Confort-Gouny, S. et al. (1992). “Metabolic Characterization of Neurological Diseases by Proton Localized NMR Spectroscopy of the Human Brain,”C. R. Acad. Sci. III315:287-293.
Contasta, I. et al. (2001). “Cell Cycle Control in Cellular Homeostasis During the Immune Response: Interactions Between TH1, TH2 Cytokines, and Bc12 and p53 Molecules,”Cancer Biotherapy&Radiopharmaceuticals16(1):63-71.
Cullen, P. et al. (1998). “Lipoproteins and Cardiovascular Risk—from Genetics to CHD Prevention,”European Heart Journal19(Suppl. C):C5-C11.
Després, J-P. et al. (2000). “HDL-Cholesterol as a Marker of Coronary Heart Disease Risk: The Québec Cardiovascular Study,”Atherosclerosis153:263-272.
Dolecek, T.A. et al. (Jun. 1986). “A Long-Term Nutrition Intervention Experience: Lipid Responses and Dietary Adherence Patterns in the Multiple Risk Factor Intervention Trial,”Journal of the American Dietetic Association86(6):752-758.
Dutt, M.J. et al. (2000). “Proteomic Analysis,”Current Opinion in Biotechnology11:176-179.
Dvorak, A.M. et al. (Aug. 1996).“Comparative Ultrastructural Morphology of Human Basophils Stimulated to Release Histamine by Anti-IgE, Recombinant IgE-Dependent Histamine-Releasing Factor, or Monocyte Chemotactic Protein-1,”J. Allergy Clin. Immunol.98(2):355-370.
Enesenat, D. et al. (2001). “Transforming Growth Factor-β1 Stimulates Vascular Smooth Muscle Cell L-Proline Transport by Inducing System A Amino Acid Transporter 2 (SAT2) Gene Expression,”Biochem. J.360:507-512.
European Search Report mailed Jan. 19, 2007, for European Application No. 02720254.8 filed on Apr. 23, 2002, nine pages.
European Search Report mailed Aug. 24, 2007, for European Application No. 02720251.4 filed on Apr. 23, 2002, seven pages.
European Search Report mailed Feb. 28, 2008, for European Application No. 02718382.1 filed on Apr. 23, 2002, four pages.
Fan, T. W-M. (1996). “Metabolite Profiling by One—and Two-Dimensional NMR Analysis of Complex Mixtures,”Progress in Nuclear Magnetic Resonance Spectroscopy28:161-219.
Farrant, R.D. et al. (1992). “An Automatic Data Reduction and Transfer Method to Aid Pattern Recognition Analysis and Classification of NMR Spectra,”Journal of Pharmaceutical&Biomedical Analysis10(2/3):141-144.
Fearn, T. (2000). “On Orthogonal Signal Correction,”Chemometrics and Intelligent Laboratory Systems50:47-52.
Fiehn, O. et al. (Nov. 2000). “Metabolite Profiling for Plant Functional Genomics,”Nature Biotechnology18:1157-1161.
Felson, D.T. et al. (Oct. 17, 2000). “Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors,”Annals of Internal Medicine13

Affiliated with

Also associated with

Rating

Methods for the diagnosis and treatment of bone disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the diagnosis and treatment of bone disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the diagnosis and treatment of bone disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2726259